Literature DB >> 26846177

Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer.

Takahiro Akahori1, Masayuki Sho2, Toshihiro Tanaka3, Shoichi Kinoshita1, Minako Nagai1, Satoshi Nishiwada1, Hideyuki Nishiofuku3, Chiho Ohbayashi4, Kimihiko Kichikawa3, Yoshiyuki Nakajima1.   

Abstract

BACKGROUND: The importance of completing adjuvant chemotherapy in pancreatic cancer is becoming recognized. However, the clinicopathological factors associated with failure to complete adjuvant chemotherapy remain unclear.
METHODS: A total of 135 patients were analyzed to identify the factors associated with failure to complete adjuvant chemotherapy.
RESULTS: Ninety patients completed planned adjuvant chemotherapy, whereas 45 patients failed to complete adjuvant chemotherapy. Lower preoperative prognostic nutritional index, intraoperative blood transfusion, and organ and/or space surgical site infection, and advanced tumor stage were associated with failure to complete adjuvant chemotherapy. Neoadjuvant chemoradiotherapy was associated with significantly lower prognostic nutritional index, less incidence of organ and/or space surgical site infection, and earlier tumor stage, suggesting the conflicting effects of neoadjuvant chemoradiotherapy on completing adjuvant chemotherapy.
CONCLUSIONS: Several clinicopathological factors including patient conditions and perioperative events were associated with failure to complete adjuvant chemotherapy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adjuvant chemotherapy; Pancreatic cancer; Prognosis; Recurrence

Mesh:

Year:  2016        PMID: 26846177     DOI: 10.1016/j.amjsurg.2015.10.034

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  9 in total

1.  Analyzing the Impact of Compliance with National Guidelines for Pancreatic Cancer Care Using the National Cancer Database.

Authors:  Kathryn Jaap; Marcus Fluck; Marie Hunsinger; Jeffrey Wild; Tania Arora; Mohsen Shabahang; Joseph Blansfield
Journal:  J Gastrointest Surg       Date:  2018-03-28       Impact factor: 3.452

2.  Prognostic Relevance of the Timing of Initiating and the Completion of Adjuvant Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Woohyung Lee; Yoo-Seok Yoon; Ho-Seong Han; Jin Young Jang; Jai Young Cho; Woohyun Jung; Wooil Kwon; YoungRok Choi; Sun-Whe Kim
Journal:  World J Surg       Date:  2017-02       Impact factor: 3.352

3.  Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft.

Authors:  Eunsung Jun; Song Cheol Kim; Chan Mi Lee; Juyun Oh; Song Lee; In Kyong Shim
Journal:  Sci Rep       Date:  2017-09-28       Impact factor: 4.379

Review 4.  Role of let-7 family microRNA in breast cancer.

Authors:  Chadrashekar Kagepura Thammaiah; Shankar Jayaram
Journal:  Noncoding RNA Res       Date:  2016-11-04

5.  Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma.

Authors:  Ilaria Trestini; Luisa Carbognin; Umberto Peretti; Isabella Sperduti; Alberto Caldart; Daniela Tregnago; Alice Avancini; Alessandra Auriemma; Giulia Orsi; Sara Pilotto; Luca Frulloni; Gabriele Capurso; Emilio Bria; Michele Reni; Giampaolo Tortora; Michele Milella
Journal:  Front Oncol       Date:  2021-09-09       Impact factor: 6.244

6.  Optimizing Nanopore Sequencing for Rapid Detection of Microbial Species and Antimicrobial Resistance in Patients at Risk of Surgical Site Infections.

Authors:  Emma Whittle; Jennifer A Yonkus; Patricio Jeraldo; Roberto Alva-Ruiz; Heidi Nelson; Michael L Kendrick; Thomas E Grys; Robin Patel; Mark J Truty; Nicholas Chia
Journal:  mSphere       Date:  2022-02-16       Impact factor: 4.389

7.  Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-blind randomized phase II study.

Authors:  Daisuke Hashimoto; Sohei Satoi; Hideki Ishikawa; Yasuhiro Kodera; Keiko Kamei; Satoshi Hirano; Tsutomu Fujii; Kenichiro Uemura; Akihiko Tsuchida; Suguru Yamada; Tomohisa Yamamoto; Kiichi Hirota; Mitsugu Sekimoto
Journal:  Trials       Date:  2022-02-12       Impact factor: 2.279

8.  Pancreatic ductal adenocarcinoma in 2017: Time to change the therapeutic algorithm?

Authors:  Stefano Crippa; Alessandra Piccioli; Giovanni Guarneri; Enrico Longo; Massimo Falconi
Journal:  Endosc Ultrasound       Date:  2017-12       Impact factor: 5.628

Review 9.  Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature.

Authors:  Ester Oneda; Alberto Zaniboni
Journal:  J Clin Med       Date:  2019-11-08       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.